




Fig. 1




Fig. 2

Payload Class	Members	Average Drug Load	Mechanism of Action
Austatins	MMAE (vedotin)	4	Microtubule Disruption
	MMAE (mafadotin)	4	
Maytansines	DM1 (emtansine)	4	
Camptothecins	Ex (exatecan)	8	Topoisomerase Inhibition

Fig. 3A




Fig. 3B




Fig. 3C

Dose dependent CHOP Induction, 72hr




Fig. 3D

IC50 CHOP Induction, 72hr




Fig. 3E




Fig. 4A






Fig. 4B

**Fig. 5A****Fig. 5B**




Fig. 5C

ADC	Antibody	Payload
T-DM1	Trastuzumab	DM1
T-MMAE	Trastuzumab	MMAE
T-Ex	Trastuzumab	Exatecan

Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6E




Fig. 6D




Fig. 7A

Names	SGD #	Clinical ADC	Conjugation Site & DAR	Payload Class	MOA
vcMMAE, Vedotin	SGD-1006	Adcetris	DAR 4	Auristatin	Microtubule disruptors
AT	SGD-4830		DAR 8		
DM1, emtansine	SGD-5351	Kadcyla	DAR 3.5, lysines	Maytansine	
DM1, mertansine	SGD-5351	IMGN-901	DAR 3.5, lysines		
DM4, rabtansine	SGD-5352	IMGN-388	DAR 3.5, lysines		
Deruxtecan, exetecan	SGD-6850	DS-8201a (Enhertu)	DAR 8	Camptothecin	Topoisomerase I inhibitor
Govitecan, SN-38	SGD-6511	Sacituzumab Govitecan (Trodelyv)	DAR 8		
SeaGen CPT, MAD-CPT	SGD-7782		DAR 8		
mp-EDA-PNU	SGD-8335		DAR 4	Anthracycline	Topoisomerase I/II inhibitors, DNA damage, ROS generation
mp-Gluc-DXZ	SGD-8248		DAR 8		
Ozogamycin	SGD-8677	Mylotarg	DAR 2-3, lysines	Calicheamicin	DNA cleavage
Tesirine	SGD-7455	ADCT-301	DAR 2.3	PBD	DNA alkylators

Fig. 7B




Fig. 7C




Fig. 7D




Fig. 7E




Fig. 7F




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D




Fig. 9A




Fig. 9B




Fig. 9C




Fig. 9D




Fig. 10A




Fig. 10B




Fig. 10C




Fig. 10D





Fig. 10E

Anti-CD40 Antibody	SEA-CD40	APX005M	ADC-1013	Selicrelumab
Developer	Seagen	Apexigen	Alligator	Roche
Antibody Class	Humanized IgG1	Humanized rabbit IgG1	Fully human IgG1	Fully human IgG2
Fc backbone modification	↑FcRγIIIa binding	↑FcγRIIa&b binding ↓FcγRIIIa binding	Native	Native
Parental antibody / source	dacetuzumab	US Patent No. 9676861B2	Korean Appl. No. 20170041790	<i>Canc. Immunol. Res.</i> , 2015, 3:236
Antibody used for activity	SEA-CD40	APX005M S267E	G12	21.4.1

Fig. 11A**Binding to FcγRIIa****Fig. 11B**




Fig. 11C




Fig. 11D




Fig. 12A




Fig. 12B




Fig. 12C




Fig. 12D




Fig. 13A




Fig. 13B




Fig. 13C




Fig. 13D




Fig. 14A




Fig. 14B




Fig. 14C




Fig. 15




Fig. 16




Fig. 17




Fig. 18A

CT26 Syngenic Model




Fig. 18B




Fig. 18C




Fig. 19




Fig. 20A




Fig. 20B




Fig. 21A




Fig. 21B




Fig. 22A




Fig. 22B




Fig. 22C




Fig. 23A




Fig. 23B





Fig. 24

Receptor Clustering & Agonism



Receptor Agonism/Synapse Formation




Fig. 25